指南与共识糖尿病

临床试验中的持续葡萄糖监测与指标:国际共识声明

Continuous glucose monitoring and metrics for clinical trials: an international consensus statement.
指南 / 共识 · Lancet Diabetes Endocrinol · 2022-12-06

该国际共识声明针对糖尿病患者的前瞻性临床研究,推荐如何使用持续葡萄糖监测(CGM)数据作为指定研究终点或支持性补充葡萄糖指标,并给出优化CGM数据收集及应评估的具体葡萄糖指标的建议,获美国临床内分泌医师协会、美国糖尿病协会等多个机构认可。

要点

  • CGM以1-5分钟间隔采集数据,可提供糖化血红蛋白(HbA1c)无法单独提供的血糖波动和无症状低血糖或高血糖信息。
  • CGM衍生指标已有标准化国际公认报告格式,应考虑用于所有糖尿病临床研究。
  • 共识推荐CGM数据可用作前瞻性临床研究的指定研究终点或支持性补充葡萄糖指标。

核心结论

  • 标准化CGM数据收集与报告可促进这些指标的使用并提高CGM数据的可解释性,可能提供HbA1c以外有助于治疗决策的信息,尤其涉及低血糖、餐后高血糖和血糖变异性。

研究设计与样本

  • 国际共识声明,由多个专业机构认可,包括美国临床内分泌医师协会、美国糖尿病协会、糖尿病护理与教育专家协会、DiabetesIndia、欧洲糖尿病研究协会、国际儿童和青少年糖尿病学会、日本糖尿病学会和青少年糖尿病研究基金会。

主要发现

  • CGM设备以1-5分钟间隔采集数据,可获得血糖波动和无症状低血糖或高血糖时段的数据。
  • CGM衍生指标为标准化、国际公认报告格式的主题。
  • 共识提供关于如何在临床研究中优化CGM衍生葡萄糖数据收集的建议,包括应评估的具体葡萄糖指标。

关键数值与推荐

  • 推荐CGM数据可用于前瞻性临床研究,作为指定研究终点或支持性补充葡萄糖指标。
  • 推荐优化临床研究中CGM衍生葡萄糖数据的收集,包括应评估的具体葡萄糖指标。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Randomised controlled trials and other prospective clinical studies for novel medical interventions in people with diabetes have traditionally reported HbA1c as the measure of average blood glucose levels for the 3 months preceding the HbA1c test date. The use of this measure highlights the long-established correlation between HbA1c and relative risk of diabetes complications; the change in the measure, before and after the therapeutic intervention, is used by regulators for the approval of medications for diabetes. However, with the increasing use of continuous glucose monitoring (CGM) in clinical practice, prospective clinical studies are also increasingly using CGM devices to collect data and evaluate glucose profiles among study participants, complementing HbA1c findings, and further assess the effects of therapeutic interventions on HbA1c. Data is collected by CGM devices at 1-5 min intervals, which obtains data on glycaemic excursions and periods of asymptomatic hypoglycaemia or hyperglycaemia (ie, details of glycaemic control that are not provided by HbA1c concentrations alone that are measured continuously and can be analysed in daily, weekly, or monthly timeframes). These CGM-derived metrics are the subject of standardised, internationally agreed reporting formats and should, therefore, be considered for use in all clinical studies in diabetes. The purpose of this consensus statement is to recommend the ways CGM data might be used in prospective clinical studies, either as a specified study endpoint or as supportive complementary glucose metrics, to provide clinical information that can be considered by investigators, regulators, companies, clinicians, and individuals with diabetes who are stakeholders in trial outcomes. In this consensus statement, we provide recommendations on how to optimise CGM-derived glucose data collection in clinical studies, including the specific glucose metrics and specific glucose metrics that should be evaluated. These recommendations have been endorsed by the American Association of Clinical Endocrinologists, the American Diabetes Association, the Association of Diabetes Care and Education Specialists, DiabetesIndia, the European Association for the Study of Diabetes, the International Society for Pediatric and Adolescent Diabetes, the Japanese Diabetes Society, and the Juvenile Diabetes Research Foundation. A standardised approach to CGM data collection and reporting in clinical trials will encourage the use of these metrics and enhance the interpretability of CGM data, which could provide useful information other than HbA1c for informing therapeutic and treatment decisions, particularly related to hypoglycaemia, postprandial hyperglycaemia, and glucose variability.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Battelino T, Alexander CM, Amiel SA, et al. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol. 2022. PMID: 36493795. doi:10.1016/S2213-8587(22)00319-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。